Denali Therapeutics Inc

Denali Therapeutics reported $3.6 million in net product revenue for the second quarter of 2026, its first full quarter of AVLAYAH sales following the therapy's March 2026 approval for Hunter syndrome. The company guided third-quarter revenue to $10 million to $12 million, citing stronger-than-anticipated initial demand and expanding payer coverage. Denali ended the quarter with $940 million in cash and marketable securities, and after receiving $195 million from the sale of a priority review voucher in July, its pro forma cash position exceeds $1.1 billion. Management also announced delays in data readouts for its frontotemporal dementia and Alzheimer's disease programs, with DNL593 and DNL628 results now expected in the first half of 2027.

The Parkinson's disease clinical trial pipeline has expanded significantly, with more than 150 companies now developing over 200 pipeline drugs, according to a new report from DelveInsight. Key companies such as NeuroDerm, Annovis Bio, Cerevance, Alto Neuroscience, Biogen, Denali Therapeutics, and Arrowhead Pharmaceuticals are evaluating new therapies, with approximately 11-plus drugs in late-stage development. Promising pipeline therapies include ND0612, Buntanetap, CVN424, ALTO-208, Pirepemat, ACD-856, DNL151, and NouvNeu001, among others, targeting mechanisms like alpha-synuclein inhibitors, GPR6 protein inhibitors, and dopamine receptor agonists. Recent milestones include Biogen and Denali Therapeutics reporting Phase IIb results for BIIB122 in May 2026, Cerevance completing enrollment in a pivotal Phase III trial for solengepras, and iRegene Therapeutics receiving RMAT designation for NouvNeu001 in January 2026. The report highlights a robust competitive landscape and ongoing advances in disease-modifying approaches for Parkinson's disease.

Denali Therapeutics announced that co-founder and CEO Ryan Watts will deliver the opening plenary address at the Alzheimer’s Association International Conference 2026 in London on July 12. The presentation will cover recent scientific advances and future opportunities in neurodegenerative disease drug development, including new insights into disease biology, biomarker use, and the potential for therapeutics to cross the blood-brain barrier. Denali is advancing multiple investigational therapies for Alzheimer’s disease that leverage its TransportVehicle platform, which has been clinically validated with the FDA accelerated approval of AVLAYAH for Hunter syndrome in March 2026. Among its pipeline, DNL628 targets tau via the Oligonucleotide TransportVehicle and began Phase 1b dosing in the first half of 2026, with proof-of-concept data expected in 2027. DNL921 targets amyloid beta via the Antibody TransportVehicle and has a Clinical Trial Application submitted, with a Phase 1/1b trial anticipated to start pending regulatory approval and potential data also in 2027.

Denali Therapeutics has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $195 million. The voucher was granted following the FDA accelerated approval of Avlayah in March 2026 for Hunter syndrome. The transaction provides a significant non-dilutive capital infusion to strengthen the company's balance sheet and advance its TransportVehicle-enabled clinical portfolio. The sale remains subject to customary closing conditions including antitrust clearance. Denali shares have gained 41.2% year to date against an industry decline of 1.7%.